'Reverse vaccine' for diabetes passes test
LOS ANGELES — A “reverse vaccine” that allows people with Type 1 diabetes to produce their own insulin has passed its first test with human subjects, according to a new study. The success points to a potential strategy for treating those in the early stages of the disease, experts said.
The therapy is designed to protect cells in the pancreas that make insulin, a hormone the body needs to convert sugars and starches into energy. In people with Type 1 diabetes, the immune system goes haywire and attacks those crucial insulin-producing cells for reasons that medical researchers don't understand.
Researchers dubbed the treatment a reverse vaccine because it suppresses the immune system, instead of stimulating it. As hoped, the experimental vaccine reduced the number of immune system “killer” cells that went on the attack.
“We're trying to turn off one specific immune response,” said Dr. Lawrence Steinman, an immunologist at Stanford University and senior author of the study published Wednesday in Science Translational Medicine.
About 1.25 million Americans have Type 1 diabetes.
Show commenting policy
TribLive commenting policy
- Obama avoids calling terrorist attacks ‘Islamice_SSRq
- Teen girl Hernandez killed by Denver police once cited for resisting arrest
- Tickets let players bring home bacon — scent
- Executive order directs standards to reflect climate change projections
- Alpha to idle two West Virginia coal mines
- Mideast-North Africa category considered for 2020 Census
- Day, night 4-digit drawings match
- Judge orders nonprofit tax form release in case against IRS
- Former GOP nominee Romney will not run for president in ’16
- House passes bill aimed at expediting natural gas exports
- Penn State University eyes changes to sexual misconduct case handling